159,106 Bristol Myers Squibb Company $BMY Shares Sold by Public Sector Pension Investment Board

Public Sector Pension Investment Board decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 26.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 437,756 shares of the biopharmaceutical company’s stock after selling 159,106 shares during the period. Public Sector Pension Investment Board’s holdings in Bristol Myers Squibb were worth $27,316,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Lazard Asset Management LLC lifted its holdings in Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after buying an additional 368,193 shares in the last quarter. Callan Family Office LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $3,575,000. Saudi Central Bank lifted its position in shares of Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock worth $8,235,000 after purchasing an additional 67,780 shares during the period. BlackRock Inc. lifted its position in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Bristol Myers Squibb by 17.4% during the second quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock valued at $123,465,000 after purchasing an additional 317,360 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BMY. TD Cowen initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. Morgan Stanley decreased their price target on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a report on Friday, October 30th. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Guggenheim reiterated a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Truist Financial set a $70.00 price target on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.46.

View Our Latest Stock Report on BMY

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $58.33 on Friday. The stock has a market capitalization of $119.23 billion, a PE ratio of 12.93, a price-to-earnings-growth ratio of 0.31 and a beta of 0.20. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64. The stock’s 50-day moving average price is $61.55 and its 200-day moving average price is $60.42. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.63 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

Key Bristol Myers Squibb News

Investors following BMY have been watching these news items:

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Julia Haller sold 3,800 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares of the company’s stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

See Also

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.